Physician profile
Ali Hamzei
NPI 1376511188
$43,471.35
in general payments reported to CMS, 2019-2025
49 companies · $12K in 2025
The $12K reported for 2025 was more than what 83% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,298 · 2020: $2,462 · 2021: $2,072 · 2022: $8,349 · 2023: $7,297 · 2024: $3,323 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,789 · Travel and Lodging: $7,564 · Consulting Fee: $4,925 · Education: $12.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,789.26 |
| Travel and Lodging | $7,563.99 |
| Consulting Fee | $4,925.00 |
| Education | $12.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $12,361.18 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Evera Mri Xt Dr Surescan |
| Boston Scientific Corporation | $7,848.62 | 2019-2025 | Farapulse, General - Therapies, Watchman Access System |
| Medtronic Vascular, INC. | $5,733.74 | 2019-2020 | |
| Biotronik INC. | $4,413.09 | 2022-2025 | Amvia Edge, Acticor 7 Vr-T Dx |
| Abbott Laboratories | $3,420.89 | 2019-2023 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $976.55 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $833.64 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $827.64 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $718.77 | 2022-2025 | Barostim Neo System |
| Amgen INC. | $674.04 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $673.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $518.30 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $371.95 | 2021-2025 | Nexletol, Nexlizet |
| Kiniksa Pharmaceuticals, LTD. | $310.69 | 2021-2023 | Arcalyst |
| Biosense Webster, INC. | $307.64 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hamzei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.